AU2025204202A1 — Fgfr/pd-1 combination therapy for the treatment of cancer

USPTO Abstract

#$%^&*AU2025204202A120250626.pdf##### ABSTRACT Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient. ABSTRACT Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient. 20 25 20 42 02 05 J un 2 02 5 A B S T R A C T J u n 2 0 2 5 P r o v i d e d h e r e i n a r e c o m b i n a t i o n t h e r a p i e s f o r t h e t r e a t m e n t o f c a n c e r . I n p a r t i c u l a r , t h e d i s c l o s e d m e t h o d s a r e d i r e c t e d t o t r e a t m e n t o f c a n c e r i n a p a t i e n t c o m p r i s i n g a d m i n i s t e r i n g a n a n t i b o d y t h a t b l o c k s t h e i n t e r a c t i o n b e t w e e n P D - 1 a n d P D - L 1 a n d a n F G F R i n h i b i t o r , w h e r e i n t h e a n t i b o d y t h a t b l o c k s t h e i n t e r a c t i o n b e t w e e n P D - 1 a n d P D - L 1 a n d t h e F G F R 2 0 2 5 2 0 4 2 0 2 0 5 i n h i b i t o r a r e a d m i n i s t e r e d i f o n e o r m o r e F G F R v a r i a n t s a r e p r e s e n t i n a b i o l o g i c a l s a m p l e f r o m t h e p a t i e n t . A B S T R A C T J u n 2 0 2 5 P r o v i d e d h e r e i n a r e c o m b i n a t i o n t h e r a p i e s f o r t h e t r e a t m e n t o f c a n c e r . I n p a r t i c u l a r , t h e d i s c l o s e d m e t h o d s a r e d i r e c t e d t o t r e a t m e n t o f c a n c e r i n a p a t i e n t c o m p r i s i n g a d m i n i s t e r i n g a n a n t i b o d y t h a t b l o c k s t h e i n t e r a c t i o n b e t w e e n P D - 1 a n d P D - L 1 a n d a n F G F R i n h i b i t o r , w h e r e i n t h e a n t i b o d y t h a t b l o c k s t h e i n t e r a c t i o n b e t w e e n P D - 1 a n d P D - L 1 a n d t h e F G F R 2 0 2 5 2 0 4 2 0 2 0 5 i n h i b i t o r a r e a d m i n i s t e r e d i f o n e o r m o r e F G F R v a r i a n t s a r e p r e s e n t i n a b i o l o g i c a l s a m p l e f r o m t h e p a t i e n t .